2025
Teaching Video NeuroImage: Painful Tonic Spasms
Zheng Y, Chu D, Moeller J. Teaching Video NeuroImage: Painful Tonic Spasms. Neurology 2025, 104: e213518. PMID: 40112270, DOI: 10.1212/wnl.0000000000213518.Peer-Reviewed Original ResearchNeuromyelitis optica spectrum disorderAquaporin-4-positive neuromyelitis optica spectrum disorderEpisodes of longitudinally extensive transverse myelitisLongitudinally extensive transverse myelitisExtensive transverse myelitisPainful tonic spasmsSodium channel blockersSpasm frequencyVoltage-gated sodium channelsMyelitis episodesSpasm-freeTransverse myelitisTonic spasmsAcute attackNeurological examinationSpinal cordSodium channelsSymptomatic treatmentResidual weaknessEctopic activityOxcarbazepineSpasmRemyelinated fibersExtremity flexionGabapentin
2024
Neuroimaging Biomarkers in Parkinson’s Disease
Holmes S, Tinaz S. Neuroimaging Biomarkers in Parkinson’s Disease. Advances In Neurobiology 2024, 40: 617-663. PMID: 39562459, DOI: 10.1007/978-3-031-69491-2_21.Peer-Reviewed Original ResearchConceptsPublic health burdenNeuroimaging biomarkersTreatment developmentRisk of developing PDParkinson's diseaseHealth burdenDiagnosis of PDMultimodal neuroimaging techniquesIdiopathic Parkinson's diseaseNon-motorDifferential diagnosis of PDNeuroimaging techniquesProdromal phaseDifferential diagnosisSymptomatic treatmentDisease progressionClinical applicationBiomarkersIsaacs’ syndrome: Clinical and paraclinical perspectives in a series of cases
Sarraf P, Shafie M, Farahmand G, Mayeli M, Shahbazi M, Magrouni H, Jameie M, Emrani B, Emrani B, Rashidi-Jazani M. Isaacs’ syndrome: Clinical and paraclinical perspectives in a series of cases. Iranian Journal Of Neurology 2024, 23: 1-14. PMID: 39431227, PMCID: PMC11489630, DOI: 10.18502/cjn.v23i1.16428.Peer-Reviewed Original ResearchLeucine-rich glioma-inactivated 1Contactin-associated protein-like 2Peripheral nerve hyperexcitabilityIsaacs' syndromeIntravenous immunoglobulinMonths of follow-upMalignancy work-upGlioma-inactivated 1Double filtration plasmapheresisProtein-like 2LGI1 antibodiesNerve hyperexcitabilityParaclinical featuresParaclinical aspectsLaboratory parametersClinical featuresFiltration plasmapheresisFavorable outcomeTherapeutic managementElectrophysiological findingsFollow-upContinuous muscle activityElectrodiagnostic assessmentSymptomatic treatmentWork-up
2022
Tracking Emergence of New Motor and Non-Motor Symptoms Using the MDS-UPDRS: A Novel Outcome Measure for Early Parkinson’s Disease?
Tosin M, Simuni T, Stebbins G, Cedarbaum J. Tracking Emergence of New Motor and Non-Motor Symptoms Using the MDS-UPDRS: A Novel Outcome Measure for Early Parkinson’s Disease? Journal Of Parkinson’s Disease 2022, 12: 1345-1351. PMID: 35466955, PMCID: PMC9198734, DOI: 10.3233/jpd-223170.Peer-Reviewed Original ResearchConceptsEmergent symptomsDisease progressionOutcome measuresParkinson's disease clinical trialsNon-motor symptomsEarly Parkinson's diseaseDaily Living ScalePatient-reported experiencesClinical rating scalesNovel outcome measuresSymptomatic treatmentPD progressionClinical trialsMedian numberDaily livingLiving ScaleParkinson's diseaseSummary scoresMDS-UPDRSUseful markerRating ScaleSTX groupProgressionStxSymptomsRole of CD4+ T Cells in Parkinson's Disease
Ghanta M, Nuthalapati P, Merchant N, Chenchula S, Hussain F, Ak A, Bhaskar L. Role of CD4+ T Cells in Parkinson's Disease. Critical Reviews In Immunology 2022, 42: 17-25. PMID: 37082948, DOI: 10.1615/critrevimmunol.2023047372.Peer-Reviewed Original ResearchConceptsCD4+ T cellsT cellsExpression of CD4+ T cellsCD4+ T cell phenotypePeripheral adaptive immunityT-cell phenotypeNervous systemMulti-system disorderDopaminergic neuronal lossCentral nervous systemTreatment of PDImmune dysfunctionSymptomatic treatmentAdaptive immunityCD4Disease pathogenesisNeuronal lossProgressive conditionAnti-inflammatoryDiseaseParkinson's diseaseTreatmentPhenotypeFunctional profiles
2021
Therapy for Alzheimer’s disease: Missing targets and functional markers?
Stoiljkovic M, Horvath TL, Hajós M. Therapy for Alzheimer’s disease: Missing targets and functional markers? Ageing Research Reviews 2021, 68: 101318. PMID: 33711510, PMCID: PMC8131215, DOI: 10.1016/j.arr.2021.101318.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseNew symptomatic treatmentsNeural network integrityClinical characteristicsNext-generation therapiesSymptomatic treatmentOutcome biomarkerTau pathologyFluid biomarkersPlasma biomarkersDisease progressionEffective therapyNeurophysiological biomarkersTreatment candidatesCerebrospinal fluidNovel biomarkersTranslational studiesTreatment interventionsDiseaseTarget engagementTherapyBiomarkersCurrent conceptsMultiple biomarkersDrug targets
2020
PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders
Jamwal S, Blackburn J, Elsworth JD. PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders. Pharmacology & Therapeutics 2020, 219: 107705. PMID: 33039420, PMCID: PMC7887032, DOI: 10.1016/j.pharmthera.2020.107705.Peer-Reviewed Original ResearchConceptsNeurodegenerative disordersParkinson's diseaseAlzheimer's diseaseParaoxonase 2Mitochondrial biogenesisNeurodegenerative diseasesHuntington's diseasePeroxisome proliferator-activated receptorProliferator-activated receptorPotential therapeutic targetDevastating neurological disorderFunction of neuronsPeroxisome proliferator-activated receptor gamma co-activator-1 alphaPharmacological-based therapiesSymptomatic treatmentCurrent therapiesClinical trialsLigand-inducible transcription factorsTherapeutic targetNeurological disordersDiseasePPARγ modulatorsProgressive lossMitochondrial dysfunctionPromising target
2019
Epilepsy and Anticonvulsant Therapy in Brain Tumor Patients
Kurz S, Schiff D, Wen P. Epilepsy and Anticonvulsant Therapy in Brain Tumor Patients. 2019, 717-728. DOI: 10.1007/978-3-030-04152-6_39.Peer-Reviewed Original ResearchBrain tumor patientsTumor patientsTumor locationAntiepileptic drugsFavorable side effect profileBrain tumorsSide effect profileAntiepileptic drug therapyHistory of seizuresFocal symptomatic epilepsyGlioneuronal tumorTumor histologyEffect profileAnticonvulsant therapyDrug therapySymptomatic epilepsySymptomatic treatmentTumorPatientsSeizure riskQuality of lifeIncreasing experienceSeizuresAnticonvulsant agentsTherapyChapter 19 Wilson Disease Psychiatric Aspects
Zimbrean P. Chapter 19 Wilson Disease Psychiatric Aspects. 2019, 215-225. DOI: 10.1016/b978-0-12-810532-0.00019-7.Peer-Reviewed Original ResearchQuality of lifeWilson's diseasePsychiatric presentationsGoals of careNewer psychotropic medicationsIrreversible cognitive declineCommon presentationNeurological findingsSymptomatic treatmentPsychotropic medicationsCurrent treatmentGeneral populationPsychiatric aspectsCognitive declineFunctional psychosesWD patientsCognitive deficitsMood instabilitySymptomsTreatmentPresentationSecondary effectsRemissionMedicationsPatientsChapter 14 Psychiatric Symptoms in WD
Zimbrean P. Chapter 14 Psychiatric Symptoms in WD. 2019, 159-170. DOI: 10.1016/b978-0-12-811077-5.00014-1.Peer-Reviewed Original ResearchWilson's diseasePsychiatric presentationsGoals of careNewer psychotropic medicationsSevere side effectsQuality of lifeIrreversible cognitive declineNeurological findingsPatients' qualitySymptomatic treatmentPsychotropic medicationsCurrent treatmentPsychiatric symptomsMood symptomsGeneral populationSide effectsFunctional psychosesCognitive declineWD patientsCognitive deficitsMood instabilitySymptomsTreatmentPresentationRemission
2018
Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD)
Wasserstein M, Dionisi-Vici C, Giugliani R, Hwu WL, Lidove O, Lukacs Z, Mengel E, Mistry PK, Schuchman EH, McGovern M. Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD). Molecular Genetics And Metabolism 2018, 126: 98-105. PMID: 30514648, PMCID: PMC7249497, DOI: 10.1016/j.ymgme.2018.11.014.Peer-Reviewed Original ResearchConceptsAcid sphingomyelinase deficiencyLifestyle modificationEvidence-informed consensus processMajor organ system involvementSphingomyelinase deficiencyAcid sphingomyelinaseLife style modificationDisease-specific treatmentOrgan system involvementInterdisciplinary clinical teamRare lysosomal storage diseaseEnzyme replacement therapyClinical assessment strategiesRecombinant human acid sphingomyelinaseLymph nodesDisease complicationsLiver diseasePatients' qualitySignificant morbiditySymptom managementSymptomatic treatmentClinical manifestationsReplacement therapyStyle modificationMultisystem involvement
2016
440P Longer term efficacy of lanreotide autogel/depot (LAN) for symptomatic treatment of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT open label study
Fisher G, Wolin E, Kunz P, Liyanage N, Mirakhur B, Lowenthal S, Pommier R, Shaheen M, Vinik A. 440P Longer term efficacy of lanreotide autogel/depot (LAN) for symptomatic treatment of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT open label study. Annals Of Oncology 2016, 27: vi144. DOI: 10.1093/annonc/mdw369.25.Peer-Reviewed Original ResearchLonger Term Efficacy of Lanreotide Autogel/Depot (LAN) for Symptomatic Treatment of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Open Label Study: 2016 ACG Presidential Poster Award
Fisher G, Wolin E, Kunz P, Liyanage N, Mirakhur B, Lowenthal S, Pommier R, Shaheen M, Vinik A. Longer Term Efficacy of Lanreotide Autogel/Depot (LAN) for Symptomatic Treatment of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Open Label Study: 2016 ACG Presidential Poster Award. The American Journal Of Gastroenterology 2016, 111: s457-s458. DOI: 10.14309/00000434-201610001-01052.Peer-Reviewed Original ResearchHippocampal network dynamics in response to α7 nACh receptors activation in amyloid-β overproducing transgenic mice
Stoiljkovic M, Kelley C, Hajós GP, Nagy D, Koenig G, Leventhal L, Hajós M. Hippocampal network dynamics in response to α7 nACh receptors activation in amyloid-β overproducing transgenic mice. Neurobiology Of Aging 2016, 45: 161-168. PMID: 27459936, DOI: 10.1016/j.neurobiolaging.2016.05.021.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseΑ7 nicotinic acetylcholine receptorEffect of α7Wild-type miceGamma oscillationsNicotinic acetylcholine receptorsHippocampal network dynamicsSymptomatic treatmentClinical findingsAD patientsSaline controlsProcognitive drugsΑ7 nAChRsTransgenic miceAcetylcholine receptorsReceptor activationCognitive functionHippocampal oscillationsMiceNeurophysiological impairmentsAgonistsPower of thetaΑ7AβSignificant differencesPharmacotherapy for Fragile X Syndrome: Progress to Date
Davenport M, Schaefer T, Friedmann K, Fitzpatrick S, Erickson C. Pharmacotherapy for Fragile X Syndrome: Progress to Date. Drugs 2016, 76: 431-445. PMID: 26858239, DOI: 10.1007/s40265-016-0542-y.Peer-Reviewed Original ResearchConceptsFragile X Mental Retardation ProteinGamma-aminobutyric acid (GABA) neurotransmissionMore objective outcome measuresPlacebo-controlled trialFragile X syndromeClinical study designObjective outcome measuresSymptomatic treatmentLoss of FMRPFuture trialsExcessive glutamateOutcome measuresSelective antagonistClinical investigationSingle treatmentStudy designSymptomatic perspectiveGenetic causeX syndromeMental retardation proteinTrialsDrug developmentTreatmentSyndromeDrugs
2001
Cholinesterase Inhibitors for Alzheimer’s Disease
Grutzendler J, Morris J. Cholinesterase Inhibitors for Alzheimer’s Disease. Drugs 2001, 61: 41-52. PMID: 11217870, DOI: 10.2165/00003495-200161010-00005.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseCholinesterase inhibitorsCommon age-related neurodegenerative diseaseDifferent safety profilesAvailability of acetylcholineUrgent public health problemAge-related neurodegenerative diseasesModerate Alzheimer's diseasePublic health problemPossible adverse effectsPrimary therapySymptomatic treatmentSafety profileChEIsCentral synapsesClinical experienceUS FoodDrug AdministrationHealth problemsBasic neurobiologyCognitive statusNeurodegenerative diseasesPatientsDiseaseAdverse effects
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply